EE05196B1 - Heteroarlsulfonlklgahelaga antraniilamiidid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad ravimpreparaadid - Google Patents

Heteroarlsulfonlklgahelaga antraniilamiidid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad ravimpreparaadid

Info

Publication number
EE05196B1
EE05196B1 EEP200300558A EEP200300558A EE05196B1 EE 05196 B1 EE05196 B1 EE 05196B1 EE P200300558 A EEP200300558 A EE P200300558A EE P200300558 A EEP200300558 A EE P200300558A EE 05196 B1 EE05196 B1 EE 05196B1
Authority
EE
Estonia
Prior art keywords
lsulfon
anthranilamides
heteroar
medicaments
chain
Prior art date
Application number
EEP200300558A
Other languages
English (en)
Estonian (et)
Inventor
Brendel Joachim
Bhme Thomas
Peukert Stefan
Kleemann Heinz-Werner
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of EE200300558A publication Critical patent/EE200300558A/xx
Publication of EE05196B1 publication Critical patent/EE05196B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/34Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
EEP200300558A 2001-06-12 2002-05-31 Heteroarlsulfonlklgahelaga antraniilamiidid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad ravimpreparaadid EE05196B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10128331A DE10128331A1 (de) 2001-06-12 2001-06-12 Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
PCT/EP2002/005956 WO2002100825A2 (de) 2001-06-12 2002-05-31 Anthranilsäureamide mit heteroarylsulfonyl-seitenkette und ihre verwendung als antiarrhythmische wirkstoffe

Publications (2)

Publication Number Publication Date
EE200300558A EE200300558A (et) 2004-02-16
EE05196B1 true EE05196B1 (et) 2009-08-17

Family

ID=7687941

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300558A EE05196B1 (et) 2001-06-12 2002-05-31 Heteroarlsulfonlklgahelaga antraniilamiidid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad ravimpreparaadid

Country Status (40)

Country Link
US (2) US6903216B2 (cg-RX-API-DMAC7.html)
EP (1) EP1399423B9 (cg-RX-API-DMAC7.html)
JP (1) JP4422477B2 (cg-RX-API-DMAC7.html)
KR (1) KR100863924B1 (cg-RX-API-DMAC7.html)
CN (1) CN1247544C (cg-RX-API-DMAC7.html)
AR (1) AR036045A1 (cg-RX-API-DMAC7.html)
AT (1) ATE378318T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002316939B2 (cg-RX-API-DMAC7.html)
BG (1) BG108415A (cg-RX-API-DMAC7.html)
BR (1) BR0210374A (cg-RX-API-DMAC7.html)
CA (1) CA2450076C (cg-RX-API-DMAC7.html)
CO (1) CO5540283A2 (cg-RX-API-DMAC7.html)
CR (1) CR7140A (cg-RX-API-DMAC7.html)
CY (1) CY1107427T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20033361A3 (cg-RX-API-DMAC7.html)
DE (2) DE10128331A1 (cg-RX-API-DMAC7.html)
DK (1) DK1399423T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP034883A (cg-RX-API-DMAC7.html)
EE (1) EE05196B1 (cg-RX-API-DMAC7.html)
ES (1) ES2295360T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20031028A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0400159A3 (cg-RX-API-DMAC7.html)
IL (2) IL159247A0 (cg-RX-API-DMAC7.html)
MA (1) MA27037A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA03010875A (cg-RX-API-DMAC7.html)
MY (1) MY138341A (cg-RX-API-DMAC7.html)
NO (1) NO20035450D0 (cg-RX-API-DMAC7.html)
NZ (1) NZ530081A (cg-RX-API-DMAC7.html)
OA (1) OA12631A (cg-RX-API-DMAC7.html)
PE (1) PE20021066A1 (cg-RX-API-DMAC7.html)
PL (1) PL364371A1 (cg-RX-API-DMAC7.html)
PT (1) PT1399423E (cg-RX-API-DMAC7.html)
RS (1) RS97703A (cg-RX-API-DMAC7.html)
RU (1) RU2293727C2 (cg-RX-API-DMAC7.html)
SK (1) SK15222003A3 (cg-RX-API-DMAC7.html)
TN (1) TNSN03134A1 (cg-RX-API-DMAC7.html)
TW (1) TWI304400B (cg-RX-API-DMAC7.html)
UA (1) UA75412C2 (cg-RX-API-DMAC7.html)
WO (1) WO2002100825A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200308520B (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10128331A1 (de) * 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
AU2003235125A1 (en) * 2002-04-26 2003-11-10 Ishihara Sangyo Kaisha, Ltd. Pyridine compounds or salts thereof and herbicides containing the same
EP1388535A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
DE10312061A1 (de) * 2003-03-18 2004-09-30 Aventis Pharma Deutschland Gmbh Kombination von Phenylcarbonsäureamiden mit Blockern des IK-Kanals und deren Verwendung zur Behandlung von Vorhofarrhythmien
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
EP1489071A1 (en) * 2003-06-18 2004-12-22 4Sc Ag N-substituted, 3,4-dihydro-1H-isoquinoline as potassium channels modulators
SG131114A1 (en) 2003-08-08 2007-04-26 Janssen Pharmaceutica Nv 2-(quinoxalin-5-ylsulfonylamino)-benzamide compounds as cck2 modulators
DE10341233A1 (de) * 2003-09-08 2005-03-24 Aventis Pharma Deutschland Gmbh Kombination von Phenylcarbonsäureamiden mit beta-Adrenozeptoren-Blockern und deren Verwendung zur Behandlung von Vorhofarrhythmien
DE102004009931A1 (de) * 2004-02-26 2005-09-15 Aventis Pharma Deutschland Gmbh Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
EA200700717A1 (ru) * 2004-09-24 2007-10-26 Янссен Фармацевтика Н.В. Сульфонамиды
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
SG163543A1 (en) * 2006-04-27 2010-08-30 Sanofi Aventis Deutschland Inhibitors of the task-1 and task-3 ion channel
WO2008124524A2 (en) * 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Aryl sulfonamide compounds as modulators of the cck2 receptor
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
CA2765611A1 (en) * 2009-06-29 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Method of preparing 1-amino-1,3,3,5,5-pentamethylcyclohexane
PT2448582T (pt) 2009-06-29 2017-07-10 Agios Pharmaceuticals Inc Compostos e composições terapêuticas
WO2011010132A1 (en) * 2009-07-21 2011-01-27 Astrazeneca Ab Sustained-release composition comprising compound 600
RU2414893C1 (ru) * 2009-11-11 2011-03-27 Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева" Четвертичное аммониевое производное новокаина, обладающее противоаритмической активностью, и способ его получения
FR2967674B1 (fr) 2010-11-23 2012-12-14 Pf Medicament Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine
GB201105659D0 (en) 2011-04-01 2011-05-18 Xention Ltd Compounds
NO3175985T3 (cg-RX-API-DMAC7.html) 2011-07-01 2018-04-28
JP2015504923A (ja) 2012-01-27 2015-02-16 ギリアード サイエンシーズ, インコーポレイテッド 後期ナトリウムイオンチャネル遮断剤およびカリウムイオンチャネル遮断剤を使用する併用療法
US9701627B2 (en) * 2014-06-16 2017-07-11 University Of Maryland, Baltimore LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders
KR20200042906A (ko) * 2017-08-07 2020-04-24 고쿠리츠다이가쿠호진 히로시마다이가쿠 신규 안트라닐산계 화합물, 및 이것을 사용한 Pin1 저해제, 염증성 질환의 치료제 및 암의 치료제

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU694465B2 (en) 1993-12-27 1998-07-23 Eisai Co. Ltd. Anthranilic acid derivative
US5670504A (en) 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
DK173062B1 (da) 1996-10-11 1999-12-13 Krueger As I Fremgangsmåde til fjernelse af opløste metaller og/eller metalloider fra et vandigt medium indeholdende samme og med et sto
US5935945A (en) 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US5969017A (en) 1996-10-31 1999-10-19 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
WO2000002851A1 (en) 1998-07-08 2000-01-20 Aventis Pharma Deutschland Gmbh Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them
JP2002523451A (ja) * 1998-09-01 2002-07-30 ブリストル−マイヤーズ スクイブ カンパニー カリウムチャネル抑制剤および方法
PL352704A1 (en) * 1999-06-24 2003-09-08 Smithkline Beecham Corporation Macrophage scavenger receptor antagonists
US6531495B1 (en) 1999-10-02 2003-03-11 Aventis Pharma Deutschland Gmbh 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
DE19947457A1 (de) * 1999-10-02 2001-04-05 Aventis Pharma Gmbh 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
DE10128331A1 (de) * 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen

Also Published As

Publication number Publication date
NO20035450D0 (no) 2003-12-08
RS97703A (sr) 2006-12-15
CN1529695A (zh) 2004-09-15
SK15222003A3 (sk) 2004-06-08
KR20040030668A (ko) 2004-04-09
US6903216B2 (en) 2005-06-07
MXPA03010875A (es) 2004-02-17
DE10128331A1 (de) 2002-12-19
HUP0400159A2 (hu) 2004-07-28
CA2450076A1 (en) 2002-12-19
AU2002316939B2 (en) 2006-11-23
TWI304400B (en) 2008-12-21
CR7140A (es) 2004-04-15
PL364371A1 (en) 2004-12-13
CZ20033361A3 (cs) 2004-05-12
EP1399423A2 (de) 2004-03-24
JP4422477B2 (ja) 2010-02-24
DK1399423T3 (da) 2008-03-17
TNSN03134A1 (en) 2005-12-23
ATE378318T1 (de) 2007-11-15
CY1107427T1 (el) 2012-12-19
IL159247A0 (en) 2004-06-01
IL159247A (en) 2010-06-16
JP2004533464A (ja) 2004-11-04
RU2004100302A (ru) 2005-04-10
US20030114499A1 (en) 2003-06-19
OA12631A (fr) 2006-06-14
KR100863924B1 (ko) 2008-10-17
PT1399423E (pt) 2008-02-07
US20050137200A1 (en) 2005-06-23
MY138341A (en) 2009-05-29
US7235664B2 (en) 2007-06-26
EP1399423B9 (de) 2008-02-27
HRP20031028A2 (en) 2005-10-31
DE50211213D1 (de) 2007-12-27
ES2295360T3 (es) 2008-04-16
ECSP034883A (es) 2004-01-28
AR036045A1 (es) 2004-08-04
PE20021066A1 (es) 2003-01-21
BG108415A (en) 2004-07-30
HK1065316A1 (en) 2005-02-18
MA27037A1 (fr) 2004-12-20
WO2002100825A2 (de) 2002-12-19
CA2450076C (en) 2010-11-30
HUP0400159A3 (en) 2008-10-28
ZA200308520B (en) 2004-09-06
CN1247544C (zh) 2006-03-29
BR0210374A (pt) 2004-07-13
WO2002100825A3 (de) 2003-12-11
RU2293727C2 (ru) 2007-02-20
EE200300558A (et) 2004-02-16
CO5540283A2 (es) 2005-07-29
EP1399423B1 (de) 2007-11-14
UA75412C2 (en) 2006-04-17
NZ530081A (en) 2005-07-29

Similar Documents

Publication Publication Date Title
EE05196B1 (et) Heteroarlsulfonlklgahelaga antraniilamiidid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad ravimpreparaadid
EE05475B1 (et) Superantigeeni sisaldav konjugaat, konjugaadi kasutamine ja konjugaati sisaldav farmatseutiline kompositsioon
EE200300369A (et) Atsüülitud indanüülamiinid, nende valmistamismeetod, kasutamine ja farmatseutiline preparaat
EE05183B1 (et) Asabitsklilised hendid, nende valmistamine ja kasutamine ravimitena ning neid sisaldav farmatseutiline kompositsioon
HUP0400467A3 (en) 2-iminopyrrolidine derivatives, pharmaceutical compositions containing them and their use
EE201300011A (et) Ksantiini derivaadid, nende valmistamine ja kasutamine ravimina
DE60142890D1 (de) 3-aminoazetidinderivate enthaltende pharmazeutische zusammensetzungen, diese derivate und deren herstellung
EE200300207A (et) Heterotsüklüülalküülpiperidiini derivaadid, nendevalmistamismeetodid ja farmatseutiline kompositsioon
NO20035298D0 (no) CDK-inhiberende pyrimider, deres fremstilling og deres anvendelse som legemidler
EE05240B1 (et) Orto- ja meta-asendatud bisarlhendid, nende kasutamine ja neid sisaldavad farmatseutilised preparaadid
EE200300370A (et) Atsüülitud 6,7,8,9-tetrahüdro-5H-bensotsükloheptenüülamiinid, nende valmistamismeetod, kasutamine ja farmatseutiline preparaat
EE200300145A (et) Asa- ja polüasanaftalenüülkarboksamiidid ja farmatseutiline kompositsioon
IL154965A0 (en) Sulfonamide derivatives, their preparation and pharmaceutical compositions containing them
EE200300529A (et) Antraniilhappe amiidid, nende kasutamine ja farmatseutiline preparaat
EE200400059A (et) Diarüültsükloalküülderivaadid, nende kasutamine ravimite valmistamiseks ning neid sisaldav ravim
EE04464B1 (et) Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE05149B1 (et) Biarlkarboksamiidid, meetod nende valmistamiseks, neid sisaldav ravimkoostis ning nende kasutamine ravis
ATE282428T1 (de) Pharmazeutische dosierungsform von amorphem nilfenavir mesylat
EE05424B1 (et) Asendatud asaindooloksoatseetpiperasiini derivaadid, neid sisaldav ravimpreparaat ning nende kasutamine ravis
EE200300110A (et) Kaneelhappe asendatud guanidiidid, nende valmistamine ja kasutamine ravimitena ning neid sisaldav ravim
EE200100009A (et) Bensimidasoolid, nende valmistamine ja kasutamineravimitena
HUP0500024A3 (en) 6-aminomorphinane derivatives, their use and pharmaceutical compositions containing them
EE200300574A (et) Aminokinoliini derivaadid, nende valmistamine, neid sisaldavad ravimkoostised ja nende kasutamine adenosiini A3-retseptori ligandidena
IL154966A0 (en) Sulfonamide derivatives, their preparation and pharmaceutical compositions containing them
HUP0401713A3 (en) Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20110531